Biomedical Research and Therapy Logo

Biomedical Research and Therapy

Oral Abstracts Open Access Logo

ID: 2036 Next-generation sequencing to evaluate frequency of BCR-ABL1 kinase domain Imatinib-resistance mutations

Chinh Q. Duong 1
Trang T. Nguyen 1
Lam V. Nguyen 1
Huy Q. Pham 1
Hien T. T. Trinh 1
Hoang C. Tran 1
Tuong Q. Le 1
Thanh H. Nguyen 1
Hai N. Truong 1
Tri A. Nguyen 1
Cuong Nguyen 1, *

  1. Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam
Correspondence to: Cuong Nguyen, Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam. Email: [email protected].
Volume & Issue: Vol. 4 No. S (2017): Abstract Proceeding: International conference INNOVATIONS IN CANCER RESEARCH AND REGENERATIVE MEDICINE 2017 | Page No.: S67 | DOI: 10.15419/bmrat.v4iS.275
Published: 2017-09-05

Online metrics

Statistics from the website

  • Abstract Views: 0
  • Galley Views: 0

Statistics from Dimensions

Statistics from PlumX
Copyright © 2017 by the author(s).

Copyright The Author(s) 2024. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

Abstract

Keywords: Chronic myeloid leukemia (CML), BCR-ABL1, imatinib resistance, tyrosine kinase inhibitor (TKI), kinase domain (KD), next-generation sequencing (NGS)

Comments